Summit Therapeutics plc

Bristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech

Summit Therapeutics and Akeso delivered mixed results from the first multi-regional Phase III study of ivonescimab, the companies’ PD-1/VEGF-targeting immunotherapy, in non-small cell lung cancer (NSC

Pfizer has thrust into the global race for a best-in-class bispecific antibody that inhibits both programmed cell death protein 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF) as it

Akeso apparently disagreed with investors’ reactions after the Chinese biotech on 25 April provided an early release of preliminary overall survival (OS) data from an interim analysis of a high-stakes